US 12,109,190 B2
Urolithins as immune response enhancers
Anurag Singh, Crissier (CH); Davide D'Amico, Renens (CH); Penelope Andreux, Eclepens (CH); William Blanco-Bose, La Croix (CH); and Christopher L. Rinsch, Morges (CH)
Assigned to Amazentis SA, Lausanne (CH)
Filed by Amazentis SA, Lausanne (CH)
Filed on Aug. 24, 2022, as Appl. No. 17/822,027.
Application 17/822,027 is a division of application No. 17/061,265, filed on Oct. 1, 2020, granted, now 11,426,380, issued on Aug. 30, 2022.
Application 17/061,265 is a division of application No. 16/398,956, filed on Apr. 30, 2019, granted, now 10,792,276, issued on Oct. 6, 2020.
Claims priority of application No. 1807051 (GB), filed on Apr. 30, 2018; and application No. 1807819 (GB), filed on May 14, 2018.
Prior Publication US 2023/0097072 A1, Mar. 30, 2023
Int. Cl. A61K 31/37 (2006.01); A61K 31/335 (2006.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01); A61K 39/39 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 19/08 (2006.01); A61P 21/00 (2006.01); A61P 31/16 (2006.01); A61P 35/00 (2006.01); C07D 311/80 (2006.01)
CPC A61K 31/37 (2013.01) [A61K 31/335 (2013.01); A61K 39/0011 (2013.01); A61K 39/145 (2013.01); A61K 39/39 (2013.01); A61P 31/16 (2018.01); A61K 2039/55 (2013.01); A61K 2039/55511 (2013.01); A61P 1/04 (2018.01); A61P 1/16 (2018.01); A61P 1/18 (2018.01); A61P 13/12 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01); A61P 19/08 (2018.01); A61P 21/00 (2018.01); A61P 35/00 (2018.01); C07D 311/80 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of vaccination comprising:
a) administering to a subject in need of vaccination an effective amount of a compound of formula (I)

OG Complex Work Unit Chemistry
and
b) administering to the subject a vaccine;
wherein the subject is a human or an animal;
A, B, C, D, W, X, Y and Z are each independently selected from H and OH;
or a salt thereof.